РУС | ENG
Карта сайта
Новости
News of Academpark
Academpark in mass media
World
2011
2010
2009
Mon 3 10 17 24
Tue 4 11 18 25
Wed 5 12 19 26
Thu 6 13 20 27
Fri 7 14 21 28
Sat 1 8 15 22 29
Sun 2 9 16 23 30
 RSS
left right

“AstraZeneca” invests in the construction of Technopark “Vorsino” more than $ 150 million

2011-04-06 Moscow, today, round table "Development of an international partnership for the modernization of the Russian pharmaceutical industry" has been held. During the event, the company “AstraZeneca” announced the laying of the "first stone" of its plant in the Kaluga Region, and signed a partnership agreement with JSC “Russian Venture Company”.“AstraZeneca” invests in the construction of Technopark “Vorsino” more than $ 150 million. According to a press release the company plans Release of the first finished products in spring of 2013, and by 2019 the volume of production on a full cycle (from creation of dosage forms to packaging) will be around 500 million pills a year.Another significant event of the event was the signing of a memorandum of understanding between “AstraZeneca Russia” and the Russian Venture Company. The parties intend to focus their efforts on the development of elements of innovation infrastructure for the modernization of biomedicine and biopharmaceuticals in the Russian Federation, as well as on promoting of development and self-organization of innovation community.Igor Agamirzyan, General Director of JSC “Russian Venture Company”: "Technologies for Life and Health, an essential part of which is Biopharma are one of the focuses of investment activity of funds established with capital of RVC. Suffice it to say that the percentage of Biopharma's companies in the portfolio of RVC funds was amounted to nearly one-third by the end of last year. Moreover, earlier this year, we have created a clustered "Biofond RVC”, which will invest both in infrastructure and in innovative projects in the field of biopharmaceuticals. I am confident that the partnership with colleagues from “AstraZeneca”, a leader in biopharmaceuticals and R & D, will be beneficial and, as we expect, will bring fruitful results. " Source: Unova.ru